Elidel Drug Interactions

Potential interactions between pimecrolimus and other medicinal products have not been systematically evaluated. Pimecrolimus is exclusively metabolised by CYP 450 3A4. Based on its minimal extent of absorption, interactions of pimecrolimus with systemically administered medicinal products are unlikely to occur (see Pharmacology: Pharmacokinetics under Actions).
The present data indicate that pimecrolimus can be used simultaneously with antibiotics, antihistamines and corticosteroids (oral/nasal/inhaled).
Due to the minimal absorption of Elidel, a potential systemic interaction with vaccination is unlikely to occur. In patients with extensive disease, it is recommended that vaccinations should be administered during treatment-free intervals.
Application of pimecrolimus to vaccination sites, as long as local reactions persist, was not studied and is therefore not recommended. In a 5-year study in infants 3 months to less than 12 months of age at enrolment with mild to moderate atopic dermatitis patients with AD who were treated with Elidel cream or TCS displayed normal immune response maturation and developed effective immunization against vaccine antigens.
There is no experience with concomitant use of immunosuppressive therapies given for atopic eczema such as UVB, UVA, PUVA, azathioprine and cyclosporin A.
Pimecrolimus has no photocarcinogenic potential in animals. However, since the relevance to man is unknown excessive exposure of the skin to ultraviolet light including light from a solarium, or therapy with PUVA, UVA or UVB should be avoided during treatment with pimecrolimus.
Rare cases of flushing, rash, burning, itching or swelling have been observed shortly after the intake of alcohol in patients using pimecrolimus cream.